Generic Medicine Info
Should be taken on an empty stomach. Take on an empty stomach at least 15 min before meals.
Left ventricular outflow tract obstruction, untreated CHF, unstable angina, recent MI (within 1 month). Severe hepatic and renal impairment (CrCl <30 mL/min). Pregnancy and lactation. Concomitant use with strong CYP3A4 inhibitors, and cyclosporin.
Special Precautions
Patient with sick sinus syndrome without a functioning pacemaker, left ventricular dysfunction, ischaemic heart disease. Mild to moderate renal and hepatic impairment. Patient Counselling This drug may cause dizziness, weakness and fatigue, if affected, do not drive or operate machinery. Monitoring Parameters Monitor heart rate and blood pressure.
Adverse Reactions
Significant: Angina pectoris, hypotension. Cardiac disorders: Tachycardia, palpitations. Gastrointestinal disorders: Dyspepsia, nausea, upper abdominal pain. General disorders and administration site conditions: Peripheral oedema, asthenia, fatigue. Musculoskeletal and connective tissue disorders: Myalgia. Nervous system disorders: Headache, dizziness. Renal and urinary disorders: Polyuria. Skin and subcutaneous tissue disorders: Rash, pruritus. Vascular disorders: Flushing.
Drug Interactions
Reduced antihypertensive effect with CYP3A4 inducers (e.g. phenytoin, rifampicin). Increased absorption with midazolam. Decreased serum concentration with metoprolol.
CIMS Class
Calcium Antagonists
ATC Classification
C08CA13 - lercanidipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Disclaimer: This information is independently developed by CIMS based on lercanidipine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in